Study | Design | No. patients | GPI (n) | Age (GPI vs Standard care) | Outcomes |
---|---|---|---|---|---|
Giri et al. [11] | Nonrandomized, prospective, observational (1995–1999) | 114 | 54 | 66 ± 14 vs 67 ± 13 | • GPI significantly improved final TIMI flow. • At 30-day follow-up, the composite event rate of death, myocardial reinfarction, and target vessel revascularization were better in the GPI group (31% vs 63%; P = 0.002). • Lower mortality (22% vs 44%; p = 0.02) and recurrent infarction rates (0% vs 10%; p = 0.05) in the GPI group. • Combination of abciximab and stents was synergistic and resulted in improvement of all components of the composite end point. |
Chan et al. [12] | Nonrandomized, prospective, observational (1993–2000) | 96 | 45 | 67 ± 11 vs 64 ± 14 vs 63 ± 16 vs 68 ± 9 (Stent+abciximab vs stent only vs PCI + abciximab vs PCI alone) | • 2.5 years of follow-up, the mortality rates for stent plus abciximab, stent only, PCI plus abciximab, and PCI alone were 33%, 43%, 61%, and 68% (P = 0.028). • Stent and abciximab resulted in higher TIMI 3 flow rates (85% vs 65%, P = 0.048). • A trend of mortality benefit with abciximab was seen at 30 months (HR 0.74, 95% CI 0.36–1.11, P = 0.11). |
Antoniucci et al. [13] | Nonrandomized, prospective, observational (1999–2001) | 77 | 44 | 66 ± 12 vs 71 ± 12 | • 1-month overall mortality rate was lower in the abciximab (18% vs 42%, P < 0.020). • No differences between groups in reinfarction and target vessel revascularization rates. • Multivariate analysis showed that abciximab therapy was the only variable independently related to 1-month mortality (OR 0.36; 95% CI 0.15–0.86, P < 0.021). |
PRAGUE-7 Tousek et al. [14] | Randomized control trial (2006–2009) | 80 | 40 | 64 ± 14 vs 68 ± 11 | • The 30-day combined outcome of death/reinfarction/stroke/new severe renal failure occurred in 42.5% in the group randomized to abciximab vs 27.5% in the standard therapy group (P = 0.24). • No differences were found in TIMI-flow after PCI or major bleeding. |
Bernat et al. [15] | Nonrandomized, observational (2006–2010) | 179 | 80 | NA | • The use of GPI (HR 0.63, 95% CI 0.40–0.96, P = 0.032) was associated with a better outcome at a-year in multivariable analysis. |
Felice et al. [16] | Nonrandomized, observational (2002–2011) | 410 | 287 | 67 ± 12 vs 73 ± 12 | • No difference at a 1-year survival rates (42.8% vs 51.6%, P = 0.56) in patients treated without vs. with abciximab. • Age, oro-tracheal intubation, post-PCI TIMI flow grade 0–1 but not abciximab use (HR, 1.08; 95% CI 0.70–1.60, P = 0.60) were independent predictors of death at 1-year follow-up. |
Kanic et al. [17] | (2009–2014) | 261 | 170 | 66.7 ± 12.5 vs 64.9 ± 12.9 | • All-cause mortality was similar between groups (46.5% vs 54.9%) at 30 days; (53.5% vs. 61.1%) at 1 year. • The adjunctive usage of GPI (OR 0.41; 95%CI 0.20–0.84; P = 0.015), and novel P2Y12 inhibitors were associated with a better 30-day survival. • Better 1-year survival was independently predicted by GPI (HR 0.62; 95%CI 0.39–0.97; P = 0.037), novel P2Y12 inhibitors, age, left main PCI, TIMI 0/1 pre-PCI, and major bleeding. |